SG10201601110VA - Compositions and methods for altering tissue specificity and improving aav9-mediated gene transfer - Google Patents
Compositions and methods for altering tissue specificity and improving aav9-mediated gene transferInfo
- Publication number
- SG10201601110VA SG10201601110VA SG10201601110VA SG10201601110VA SG10201601110VA SG 10201601110V A SG10201601110V A SG 10201601110VA SG 10201601110V A SG10201601110V A SG 10201601110VA SG 10201601110V A SG10201601110V A SG 10201601110VA SG 10201601110V A SG10201601110V A SG 10201601110VA
- Authority
- SG
- Singapore
- Prior art keywords
- aav9
- compositions
- improving
- methods
- gene transfer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14041—Use of virus, viral particle or viral elements as a vector
- C12N2750/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14041—Use of virus, viral particle or viral elements as a vector
- C12N2750/14045—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/6027—Vectors comprising as targeting moiety peptide derived from defined protein from viruses ssDNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161443879P | 2011-02-17 | 2011-02-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201601110VA true SG10201601110VA (en) | 2016-03-30 |
Family
ID=45757234
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202007803QA SG10202007803QA (en) | 2011-02-17 | 2012-02-17 | Compositions and methods for altering tissue specificity and improving aav9-mediated gene transfer |
| SG10201601110VA SG10201601110VA (en) | 2011-02-17 | 2012-02-17 | Compositions and methods for altering tissue specificity and improving aav9-mediated gene transfer |
| SG2013058920A SG192268A1 (en) | 2011-02-17 | 2012-02-17 | Compositions and methods for altering tissue specificity and improving aav9-mediated gene transfer |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202007803QA SG10202007803QA (en) | 2011-02-17 | 2012-02-17 | Compositions and methods for altering tissue specificity and improving aav9-mediated gene transfer |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2013058920A SG192268A1 (en) | 2011-02-17 | 2012-02-17 | Compositions and methods for altering tissue specificity and improving aav9-mediated gene transfer |
Country Status (16)
| Country | Link |
|---|---|
| US (5) | US9884071B2 (es) |
| EP (1) | EP2675902B1 (es) |
| JP (1) | JP6224459B2 (es) |
| KR (1) | KR101956885B1 (es) |
| CN (1) | CN103502458B (es) |
| AU (1) | AU2012219380B2 (es) |
| BR (1) | BR112013020734A2 (es) |
| CA (1) | CA2826316C (es) |
| DK (1) | DK2675902T3 (es) |
| ES (1) | ES2724800T3 (es) |
| HU (1) | HUE043921T2 (es) |
| MX (1) | MX353930B (es) |
| PL (1) | PL2675902T3 (es) |
| SG (3) | SG10202007803QA (es) |
| TR (1) | TR201908020T4 (es) |
| WO (1) | WO2012112832A1 (es) |
Families Citing this family (102)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102212558B (zh) * | 2003-09-30 | 2016-08-03 | 宾夕法尼亚大学托管会 | 腺伴随病毒(aav)进化支、序列、含有这些序列的载体及它们的应用 |
| US9217155B2 (en) | 2008-05-28 | 2015-12-22 | University Of Massachusetts | Isolation of novel AAV'S and uses thereof |
| US8734809B2 (en) | 2009-05-28 | 2014-05-27 | University Of Massachusetts | AAV's and uses thereof |
| EP3444346B1 (en) | 2010-04-23 | 2022-07-27 | University of Massachusetts | Aav-based treatment of cholesterol-related disorders |
| DK2561073T3 (en) | 2010-04-23 | 2016-12-12 | Univ Massachusetts | Aav vectors targeted to central nervous system and methods of use thereof |
| EP4234571A3 (en) * | 2011-02-10 | 2023-09-27 | The University of North Carolina at Chapel Hill | Viral vectors with modified transduction profiles and methods of making and using the same |
| JP6224459B2 (ja) | 2011-02-17 | 2017-11-01 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 組織特異性を改変し、ａａｖ９媒介遺伝子導入を改善するための組成物および方法 |
| EP3318635A1 (en) | 2011-04-21 | 2018-05-09 | University of Massachusetts | Raav-based compositions and methods for treating alpha-1 anti-trypsin deficiencies |
| US9677088B2 (en) | 2012-05-09 | 2017-06-13 | Oregon Health & Science University | Adeno associated virus plasmids and vectors |
| EP2749569A1 (en) | 2012-12-28 | 2014-07-02 | Annibale Alessandro Puca | Variant of BPIFB4 protein |
| US20140219964A1 (en) | 2013-02-07 | 2014-08-07 | Children's Medical Center Corporation | Methods for inducing cardiomyocyte proliferation |
| JP2016514152A (ja) * | 2013-03-13 | 2016-05-19 | ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア | アデノ随伴ウイルスベクターおよびその使用の方法 |
| PL2984166T3 (pl) | 2013-03-15 | 2021-01-11 | The Trustees Of The University Of Pennsylvania | Kompozycje do leczenia mpsi |
| AU2014227766B2 (en) * | 2013-03-15 | 2018-10-04 | The University Of North Carolina At Chapel Hill | Methods and compositions for dual glycan binding AAV vectors |
| RS64611B1 (sr) | 2014-03-21 | 2023-10-31 | Genzyme Corp | Genska terapija za retinitis pigmentozu |
| WO2015164757A1 (en) * | 2014-04-25 | 2015-10-29 | Oregon Health & Science University | Methods of viral neutralizing antibody epitope mapping |
| WO2015187825A2 (en) | 2014-06-03 | 2015-12-10 | University Of Massachusetts | Compositions and methods for modulating dysferlin expression |
| US10577627B2 (en) | 2014-06-09 | 2020-03-03 | Voyager Therapeutics, Inc. | Chimeric capsids |
| CA2961523A1 (en) | 2014-09-16 | 2016-03-24 | Genzyme Corporation | Adeno-associated viral vectors for treating myocilin (myoc) glaucoma |
| EP4012035A1 (en) | 2014-09-16 | 2022-06-15 | Genzyme Corporation | Adeno-associated viral vectors for treating myocilin (myoc) glaucoma |
| EP3795580A1 (en) | 2014-10-03 | 2021-03-24 | University of Massachusetts | High efficiency library-identified aav vectors |
| WO2016054554A1 (en) | 2014-10-03 | 2016-04-07 | University Of Massachusetts | Heterologous targeting peptide grafted aavs |
| US10480011B2 (en) | 2014-10-21 | 2019-11-19 | University Of Massachusetts | Recombinant AAV variants and uses thereof |
| EP3215191A4 (en) | 2014-11-05 | 2018-08-01 | Voyager Therapeutics, Inc. | Aadc polynucleotides for the treatment of parkinson's disease |
| MX2017006216A (es) | 2014-11-14 | 2018-08-29 | Voyager Therapeutics Inc | Composiciones y métodos para tratar la esclerosis lateral amiotrófica (ela). |
| EP3907287A1 (en) | 2014-11-14 | 2021-11-10 | Voyager Therapeutics, Inc. | Modulatory polynucleotides |
| WO2016094783A1 (en) | 2014-12-12 | 2016-06-16 | Voyager Therapeutics, Inc. | Compositions and methods for the production of scaav |
| TWI745285B (zh) | 2015-01-20 | 2021-11-11 | 美商健臻公司 | 用於重組病毒粒子特徵化之分析性超速離心法 |
| CA2976075A1 (en) | 2015-02-10 | 2016-08-18 | Genzyme Corporation | Variant rnai |
| LT3256594T (lt) | 2015-02-10 | 2022-02-10 | Genzyme Corporation | Patobulintas virusinių dalelių tiekimas į dryžuotąjį kūną ir smegenų žievę |
| US10584321B2 (en) | 2015-02-13 | 2020-03-10 | University Of Massachusetts | Compositions and methods for transient delivery of nucleases |
| TWI707951B (zh) | 2015-04-08 | 2020-10-21 | 美商健臻公司 | 過大腺相關載體之製造 |
| EP3285780A4 (en) | 2015-04-24 | 2018-12-19 | University of Massachusetts | Modified aav constructions and uses thereof |
| MX2017014665A (es) | 2015-05-16 | 2018-04-24 | Genzyme Corp | Edicion de genes de mutaciones intronicas profundas. |
| WO2017019876A1 (en) * | 2015-07-28 | 2017-02-02 | University Of Massachusetts | Transgenic expression of dnase i in vivo delivered by an adeno-associated virus vector |
| CA3002982A1 (en) | 2015-10-22 | 2017-04-27 | University Of Massachusetts | Methods and compositions for treating metabolic imbalance in neurodegenerative disease |
| EP3364996B1 (en) | 2015-10-22 | 2021-08-25 | University of Massachusetts | Prostate-targeting adeno-associated virus serotype vectors |
| AU2016362477A1 (en) | 2015-12-02 | 2018-06-14 | Voyager Therapeutics, Inc. | Assays for the detection of AAV neutralizing antibodies |
| US11015174B2 (en) | 2015-12-11 | 2021-05-25 | The Trustees Of The University Of Pennsylvania | Scalable purification method for AAV8 |
| EP3992283A1 (en) | 2015-12-11 | 2022-05-04 | The Trustees Of The University Of Pennsylvania | Scalable purification method for aavrh10 |
| WO2017160360A2 (en) | 2015-12-11 | 2017-09-21 | The Trustees Of The University Of Pennsylvania | Scalable purification method for aav9 |
| WO2017100674A1 (en) | 2015-12-11 | 2017-06-15 | The Trustees Of The University Of Pennsylvania | Scalable purification method for aav1 |
| AU2016372035B2 (en) | 2015-12-15 | 2023-03-30 | Genzyme Corporation | Adeno-associated viral vectors for treating mucolipidosis type ii |
| WO2017136536A1 (en) | 2016-02-02 | 2017-08-10 | University Of Massachusetts | Method to enhance the efficiency of systemic aav gene delivery to the central nervous system |
| SG11201806270XA (en) | 2016-02-03 | 2018-08-30 | Univ Pennsylvania | Gene therapy for treating mucopolysaccharidosis type i |
| US11060088B2 (en) | 2016-02-12 | 2021-07-13 | University Of Massachusetts | Anti-angiogenic miRNA therapeutics for inhibiting corneal neovascularization |
| US11207426B2 (en) | 2016-04-05 | 2021-12-28 | University Of Massachusetts | Compositions and methods for selective inhibition of grainyhead-like protein expression |
| CA3019427A1 (en) | 2016-04-15 | 2017-10-19 | The Trustees Of The University Of Pennsylvania | Gene therapy for treating mucopolysaccharidosis type ii |
| US11413356B2 (en) | 2016-04-15 | 2022-08-16 | University Of Massachusetts | Methods and compositions for treating metabolic imbalance |
| WO2017189964A2 (en) | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| US11326182B2 (en) | 2016-04-29 | 2022-05-10 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| CN116333057A (zh) | 2016-05-13 | 2023-06-27 | 4D分子治疗有限公司 | 腺相关病毒变体衣壳和其使用方法 |
| CN109831916B (zh) | 2016-05-18 | 2023-07-21 | 沃雅戈治疗公司 | 治疗亨廷顿氏舞蹈病的组合物和方法 |
| JP7066635B2 (ja) | 2016-05-18 | 2022-05-13 | ボイジャー セラピューティクス インコーポレイテッド | 調節性ポリヌクレオチド |
| US11882815B2 (en) | 2016-06-15 | 2024-01-30 | University Of Massachusetts | Recombinant adeno-associated viruses for delivering gene editing molecules to embryonic cells |
| CN106093369B (zh) * | 2016-06-29 | 2017-10-20 | 福建农林大学 | Bt水稻对非靶标害虫褐飞虱的安全性评价方法 |
| DK3497207T3 (da) | 2016-08-15 | 2021-03-22 | Genzyme Corp | Fremgangsmåder til påvisning af aav |
| CN110650673B (zh) | 2016-08-30 | 2024-04-09 | 加利福尼亚大学董事会 | 用于生物医学靶向和递送的方法以及用于实践该方法的装置和*** |
| US10457940B2 (en) | 2016-09-22 | 2019-10-29 | University Of Massachusetts | AAV treatment of Huntington's disease |
| US11578340B2 (en) | 2016-10-13 | 2023-02-14 | University Of Massachusetts | AAV capsid designs |
| WO2018119330A2 (en) * | 2016-12-22 | 2018-06-28 | Oregon Health & Science University | Adeno associated viral vectors |
| AU2018261790A1 (en) | 2017-05-05 | 2019-11-28 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (ALS) |
| AU2018261003A1 (en) | 2017-05-05 | 2019-11-14 | Voyager Therapeutics, Inc. | Compositions and methods of treating Huntington's Disease |
| JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
| EP3676385A1 (en) | 2017-07-06 | 2020-07-08 | The Trustees of The University of Pennsylvania | Aav9-mediated gene therapy for treating mucopolysaccharidosis type i |
| AU2018302016A1 (en) | 2017-07-17 | 2020-02-06 | The Regents Of The University Of California | Trajectory array guide system |
| CA3076348A1 (en) | 2017-09-20 | 2019-03-28 | 4D Molecular Therapeutics Inc. | Adeno-associated virus variant capsids and methods of use thereof |
| EP3684938A1 (en) | 2017-09-22 | 2020-07-29 | The Trustees of the University of Pennsylvania | Gene therapy for treating mucopolysaccharidosis type ii |
| JP7248658B2 (ja) | 2017-09-22 | 2023-03-29 | ジェンザイム・コーポレーション | バリアントＲＮＡｉ |
| TW202413649A (zh) | 2017-10-16 | 2024-04-01 | 美商航海家醫療公司 | 肌萎縮性脊髓側索硬化症(als)之治療 |
| WO2019079242A1 (en) | 2017-10-16 | 2019-04-25 | Voyager Therapeutics, Inc. | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) |
| FI3717636T3 (fi) | 2017-11-27 | 2023-06-01 | 4D Molecular Therapeutics Inc | Adenoassosioidun viruksen kapsidivariantteja ja käyttö angiogeneesin estämisessä |
| KR20230065367A (ko) * | 2018-02-01 | 2023-05-11 | 호몰로지 메디슨, 인크. | Pah 유전자 전달을 위한 아데노-연관 바이러스 조성물 및 이의 사용 방법 |
| US10610606B2 (en) | 2018-02-01 | 2020-04-07 | Homology Medicines, Inc. | Adeno-associated virus compositions for PAH gene transfer and methods of use thereof |
| US11306329B2 (en) | 2018-02-19 | 2022-04-19 | City Of Hope | Adeno-associated virus compositions for restoring F8 gene function and methods of use thereof |
| CA3093347A1 (en) | 2018-04-05 | 2019-10-10 | Genethon | Hybrid recombinant adeno-associated virus serotype between aav9 and aavrh74 with reduced liver tropism |
| CN112351787A (zh) * | 2018-05-04 | 2021-02-09 | 俄勒冈健康与科学大学 | 人抗aav2衣壳多克隆抗体表位 |
| WO2019241486A1 (en) | 2018-06-13 | 2019-12-19 | Voyager Therapeutics, Inc. | Engineered 5' untranslated regions (5' utr) for aav production |
| MX2021000810A (es) | 2018-07-24 | 2021-04-28 | Voyager Therapeutics Inc | Sistemas y metodos para producir formulaciones de terapia genetica. |
| WO2020028816A1 (en) | 2018-08-03 | 2020-02-06 | Genzyme Corporation | Variant rnai against alpha-synuclein |
| WO2020072849A1 (en) | 2018-10-04 | 2020-04-09 | Voyager Therapeutics, Inc. | Methods for measuring the titer and potency of viral vector particles |
| TW202028458A (zh) | 2018-10-05 | 2020-08-01 | 美商航海家醫療公司 | 編碼腺相關病毒(aav)生產蛋白之經基因工程化核酸構築體 |
| AU2019357039A1 (en) | 2018-10-12 | 2021-06-03 | Genzyme Corporation | Generation of improved human pah for treatment of severe PKU by liver-directed gene replacement therapy |
| UY38407A (es) | 2018-10-15 | 2020-05-29 | Novartis Ag | Anticuerpos estabilizadores de trem2 |
| TW202028468A (zh) | 2018-10-15 | 2020-08-01 | 美商航海家醫療公司 | 用於桿狀病毒/Sf9系統中rAAV之大規模生產的表現載體 |
| CN113924115A (zh) * | 2019-01-31 | 2022-01-11 | 俄勒冈健康与科学大学 | 用于aav衣壳的使用转录依赖性定向进化的方法 |
| JP2022520875A (ja) | 2019-02-25 | 2022-04-01 | ノバルティス アーゲー | Ｂｉｅｔｔｉクリスタリン網膜症を治療するための組成物及び方法 |
| KR20210132684A (ko) | 2019-02-25 | 2021-11-04 | 노파르티스 아게 | 비에띠 결정 이상증을 치료하기 위한 조성물 및 방법 |
| CN113557010A (zh) | 2019-02-28 | 2021-10-26 | 瑞泽恩制药公司 | 用于递送治疗剂的腺相关病毒载体 |
| WO2020210595A1 (en) * | 2019-04-12 | 2020-10-15 | University Of Massachusetts | Aav-mediated gene therapy for maple syrup urine disease (msud) |
| US10653731B1 (en) | 2019-07-15 | 2020-05-19 | Vigene Biosciences Inc. | Recombinantly-modified adeno-associated virus (rAAV) having improved packaging efficiency |
| US10801042B1 (en) | 2019-07-15 | 2020-10-13 | Vigene Biosciences, Inc. | Use of ion concentrations to increase the packaging efficiency of recombinant adeno-associated virus |
| US10557149B1 (en) | 2019-07-15 | 2020-02-11 | Vigene Biosciences, Inc. | Recombinantly-modified adeno-associated virus helper vectors and their use to improve the packaging efficiency of recombinantly-modified adeno-associated virus |
| WO2021087366A1 (en) * | 2019-11-01 | 2021-05-06 | Sangamo Therapeutics, Inc. | Compositions and methods for genome engineering |
| TW202140791A (zh) | 2020-01-13 | 2021-11-01 | 美商霍蒙拉奇醫藥公司 | 治療苯酮尿症之方法 |
| EP4222251A1 (en) | 2020-10-01 | 2023-08-09 | Genzyme Corporation | Human pah expression cassette for treatment of pku by liver-directed gene replacement therapy |
| EP4284335A1 (en) | 2021-02-01 | 2023-12-06 | RegenxBio Inc. | Gene therapy for neuronal ceroid lipofuscinoses |
| WO2023010135A1 (en) | 2021-07-30 | 2023-02-02 | Tune Therapeutics, Inc. | Compositions and methods for modulating expression of methyl-cpg binding protein 2 (mecp2) |
| CA3227103A1 (en) | 2021-07-30 | 2023-02-02 | Matthew P. GEMBERLING | Compositions and methods for modulating expression of frataxin (fxn) |
| WO2023147304A1 (en) * | 2022-01-25 | 2023-08-03 | The Trustees Of The University Of Pennsylvania | Aav capsids for improved heart transduction and detargeting of liver |
| WO2023214346A1 (en) | 2022-05-06 | 2023-11-09 | Novartis Ag | Novel recombinant aav vp2 fusion polypeptides |
| WO2024015881A2 (en) | 2022-07-12 | 2024-01-18 | Tune Therapeutics, Inc. | Compositions, systems, and methods for targeted transcriptional activation |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5774090A (en) | 1980-10-27 | 1982-05-10 | Shionogi & Co Ltd | Novel beta-galactosidase inhibitor, gt-2558, its derivative, and production |
| US4886876A (en) | 1983-03-31 | 1989-12-12 | Scripps Clinic And Research Foundation | Factor VIII coagulant polypeptides |
| US4542104A (en) | 1983-04-06 | 1985-09-17 | The Board Of Trustees Of The Leland Stanford Jr. Univ. | Phycobiliprotein fluorescent conjugates |
| US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
| WO1985001961A1 (en) | 1983-10-28 | 1985-05-09 | Genetics Institute | Production of factor viii and related products |
| US5045455A (en) | 1984-01-12 | 1991-09-03 | Chiron Corporation | Factor VIII:C cDNA cloning and expression |
| FI86885C (fi) | 1984-04-20 | 1992-10-26 | Genentech Inc | Foerfarande foer framstaellning av human rekombinantfaktor viii och nukleinsyrasekvenser och vektorer anvaend daertill |
| US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
| EP0182448A3 (en) | 1984-08-24 | 1987-10-28 | Genetics Institute, Inc. | Production of factor viii and related products |
| FI98829C (fi) | 1986-01-27 | 1997-08-25 | Chiron Corp | Menetelmä rekombinoidun proteiinikompleksin valmistamiseksi, jolla on humaanitekijä VIII:C-aktiivisuutta |
| US5595886A (en) | 1986-01-27 | 1997-01-21 | Chiron Corporation | Protein complexes having Factor VIII:C activity and production thereof |
| US5422260A (en) | 1986-05-29 | 1995-06-06 | Genetics Institute, Inc. -Legal Affairs | Human factor VIII:c muteins |
| US5451521A (en) | 1986-05-29 | 1995-09-19 | Genetics Institute, Inc. | Procoagulant proteins |
| US5149637A (en) | 1987-04-06 | 1992-09-22 | Scripps Clinic & Research Foundation | Recombinant Factor VIIIC fragments |
| IL86693A (en) | 1987-06-12 | 1994-06-24 | Stichting Centraal Lab | Proteins that have the activity IIIV of the blood, a process for their preparation that uses cells are produced through genetic engineering and pharmaceutical preparations that contain them |
| FR2619314B1 (fr) | 1987-08-11 | 1990-06-15 | Transgene Sa | Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant |
| US5004803A (en) | 1988-11-14 | 1991-04-02 | Genetics Institute, Inc. | Production of procoagulant proteins |
| EP0500734B1 (en) | 1989-11-17 | 1998-02-11 | Novo Nordisk A/S | Protein complexes having factor viii:c activity and production thereof |
| SE465222C5 (sv) | 1989-12-15 | 1998-02-10 | Pharmacia & Upjohn Ab | Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning |
| US5171846A (en) | 1990-05-21 | 1992-12-15 | Coulter Corporation | Method of preferential labelling of a phycobiliprotein with a second dye for use in a multiple color assay and product for such use |
| US5272257A (en) | 1990-05-21 | 1993-12-21 | Coulter Corporation | Method of preferential labelling of a phycobiliprotein with an amine-reactive dye for use in a multiple color assay and product for such use |
| US5240640A (en) | 1990-06-04 | 1993-08-31 | Coulter Corporation | In situ use of gelatin or an aminodextran in the preparation of uniform ferrite particles |
| US5639620A (en) | 1990-10-31 | 1997-06-17 | Coulter Corporation | Polymeric particles having a biodegradable gelatin or aminodextran coating and process for making same |
| US5466609A (en) | 1990-10-31 | 1995-11-14 | Coulter Corporation | Biodegradable gelatin-aminodextran particle coatings of and processes for making same |
| SE468050C (sv) | 1991-03-15 | 1998-04-27 | Pharmacia & Upjohn Ab | Rekombinant derivat av human faktor VIII |
| US5661008A (en) | 1991-03-15 | 1997-08-26 | Kabi Pharmacia Ab | Recombinant human factor VIII derivatives |
| US5248771A (en) | 1991-06-26 | 1993-09-28 | Triumf | Process for preparing no-carrier-added radiohalogenated vinyl nucleosides |
| CA2078721A1 (en) | 1991-09-24 | 1993-03-25 | Hiroshi Yonemura | Process for preparing human coagulation factor viii protein complex |
| US5248772A (en) | 1992-01-29 | 1993-09-28 | Coulter Corporation | Formation of colloidal metal dispersions using aminodextrans as reductants and protective agents |
| WO1994011013A1 (en) | 1992-11-13 | 1994-05-26 | Duke University | Chimeric blood coagulation proteins |
| US5563045A (en) | 1992-11-13 | 1996-10-08 | Genetics Institute, Inc. | Chimeric procoagulant proteins |
| US5478745A (en) | 1992-12-04 | 1995-12-26 | University Of Pittsburgh | Recombinant viral vector system |
| EP0874057B1 (en) | 1993-06-10 | 2004-07-28 | Bayer Corporation | Vector and mammalian cell line having improved productivity |
| CA2164646A1 (en) | 1993-06-11 | 1994-12-22 | Wade E. Bolton | Anti-cd3 antibody-aminodextran conjugates for induction of t-cell activation and proliferation |
| US5681746A (en) | 1994-12-30 | 1997-10-28 | Chiron Viagene, Inc. | Retroviral delivery of full length factor VIII |
| WO1997003195A1 (en) | 1995-07-11 | 1997-01-30 | Chiron Corporation | Novel factor viii:c polypeptide analogs with altered protease sites |
| CA2264482A1 (en) | 1996-09-06 | 1998-03-12 | The Trustees Of The University Of Pennsylvania | An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase |
| US6096273A (en) | 1996-11-05 | 2000-08-01 | Clinical Micro Sensors | Electrodes linked via conductive oligomers to nucleic acids |
| US5945293A (en) | 1997-10-09 | 1999-08-31 | Coulter International Corp. | Protein-colloidal metal-aminodextran coated particle and methods of preparation and use |
| US6074884A (en) | 1997-10-09 | 2000-06-13 | Coulter International Corp. | Stable protein-nickel particles and methods of production and use thereof |
| US6117643A (en) | 1997-11-25 | 2000-09-12 | Ut Battelle, Llc | Bioluminescent bioreporter integrated circuit |
| US6197503B1 (en) | 1997-11-26 | 2001-03-06 | Ut-Battelle, Llc | Integrated circuit biochip microsystem containing lens |
| US6287857B1 (en) * | 1998-02-09 | 2001-09-11 | Genzyme Corporation | Nucleic acid delivery vehicles |
| WO2000014197A1 (fr) | 1998-09-09 | 2000-03-16 | Hitachi Software Engineering Co., Ltd. | Biopuce et procede d'utilisation de la biopuce |
| US6221349B1 (en) | 1998-10-20 | 2001-04-24 | Avigen, Inc. | Adeno-associated vectors for expression of factor VIII by target cells |
| US6200560B1 (en) | 1998-10-20 | 2001-03-13 | Avigen, Inc. | Adeno-associated virus vectors for expression of factor VIII by target cells |
| CN102212558B (zh) * | 2003-09-30 | 2016-08-03 | 宾夕法尼亚大学托管会 | 腺伴随病毒(aav)进化支、序列、含有这些序列的载体及它们的应用 |
| WO2006119432A2 (en) * | 2005-04-29 | 2006-11-09 | The Government Of The U.S.A., As Rep. By The Sec., Dept. Of Health & Human Services | Isolation, cloning and characterization of new adeno-associated virus (aav) serotypes |
| JP6174318B2 (ja) * | 2009-04-30 | 2017-08-02 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | アデノ随伴ウイルス構築物を含んでなるコンダクティング気道細胞を標的とするための組成物 |
| JP5458245B2 (ja) | 2010-06-25 | 2014-04-02 | 国立大学法人九州工業大学 | 動作制御装置、その方法、及びプログラム |
| WO2012109214A1 (en) * | 2011-02-07 | 2012-08-16 | The University Of North Carolina At Chapel Hill | Targeted transduction of aav vectors |
| EP4234571A3 (en) * | 2011-02-10 | 2023-09-27 | The University of North Carolina at Chapel Hill | Viral vectors with modified transduction profiles and methods of making and using the same |
| JP6224459B2 (ja) | 2011-02-17 | 2017-11-01 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 組織特異性を改変し、ａａｖ９媒介遺伝子導入を改善するための組成物および方法 |
-
2012
- 2012-02-17 JP JP2013554622A patent/JP6224459B2/ja active Active
- 2012-02-17 DK DK12705773.5T patent/DK2675902T3/da active
- 2012-02-17 HU HUE12705773A patent/HUE043921T2/hu unknown
- 2012-02-17 ES ES12705773T patent/ES2724800T3/es active Active
- 2012-02-17 TR TR2019/08020T patent/TR201908020T4/tr unknown
- 2012-02-17 MX MX2013009538A patent/MX353930B/es active IP Right Grant
- 2012-02-17 SG SG10202007803QA patent/SG10202007803QA/en unknown
- 2012-02-17 KR KR1020137023589A patent/KR101956885B1/ko active IP Right Grant
- 2012-02-17 WO PCT/US2012/025550 patent/WO2012112832A1/en active Application Filing
- 2012-02-17 SG SG10201601110VA patent/SG10201601110VA/en unknown
- 2012-02-17 CN CN201280008862.8A patent/CN103502458B/zh active Active
- 2012-02-17 AU AU2012219380A patent/AU2012219380B2/en active Active
- 2012-02-17 PL PL12705773T patent/PL2675902T3/pl unknown
- 2012-02-17 EP EP12705773.5A patent/EP2675902B1/en active Active
- 2012-02-17 CA CA2826316A patent/CA2826316C/en active Active
- 2012-02-17 SG SG2013058920A patent/SG192268A1/en unknown
- 2012-02-17 BR BR112013020734A patent/BR112013020734A2/pt not_active Application Discontinuation
- 2012-02-17 US US13/985,630 patent/US9884071B2/en active Active
-
2018
- 2018-01-05 US US15/862,999 patent/US10406173B2/en active Active
-
2019
- 2019-09-09 US US16/564,537 patent/US10918658B2/en active Active
-
2021
- 2021-01-27 US US17/159,735 patent/US11766448B2/en active Active
-
2023
- 2023-08-15 US US18/450,130 patent/US20240082288A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US10918658B2 (en) | 2021-02-16 |
| TR201908020T4 (tr) | 2019-06-21 |
| US20240082288A1 (en) | 2024-03-14 |
| US9884071B2 (en) | 2018-02-06 |
| JP2014507154A (ja) | 2014-03-27 |
| CA2826316C (en) | 2021-04-27 |
| EP2675902A1 (en) | 2013-12-25 |
| US11766448B2 (en) | 2023-09-26 |
| AU2012219380A1 (en) | 2013-08-29 |
| CN103502458A (zh) | 2014-01-08 |
| US20130323226A1 (en) | 2013-12-05 |
| EP2675902B1 (en) | 2019-03-27 |
| AU2012219380B2 (en) | 2017-04-13 |
| KR101956885B1 (ko) | 2019-03-12 |
| JP6224459B2 (ja) | 2017-11-01 |
| SG10202007803QA (en) | 2020-09-29 |
| US20210145857A1 (en) | 2021-05-20 |
| ES2724800T3 (es) | 2019-09-16 |
| SG192268A1 (en) | 2013-08-30 |
| DK2675902T3 (da) | 2019-06-03 |
| KR20140046407A (ko) | 2014-04-18 |
| CA2826316A1 (en) | 2012-08-23 |
| US20200101099A1 (en) | 2020-04-02 |
| MX353930B (es) | 2018-02-02 |
| US10406173B2 (en) | 2019-09-10 |
| CN103502458B (zh) | 2016-11-16 |
| HUE043921T2 (hu) | 2019-09-30 |
| MX2013009538A (es) | 2013-09-26 |
| BR112013020734A2 (pt) | 2017-06-13 |
| US20180185405A1 (en) | 2018-07-05 |
| WO2012112832A1 (en) | 2012-08-23 |
| PL2675902T3 (pl) | 2019-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10202007803QA (en) | Compositions and methods for altering tissue specificity and improving aav9-mediated gene transfer | |
| HK1246715A1 (zh) | 用於靶向熱調節的組合物和方法 | |
| HK1207663A1 (en) | Composition and methods for highly efficient gene transfer using aav capsid variants aav | |
| AP3907A (en) | 3-Pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH | |
| PL3260558T3 (pl) | Nowe kompozycje i sposoby poprawy specyficzności pcr | |
| HK1200190A1 (en) | Targeted enzyme compounds and uses thereof | |
| EP2691121A4 (en) | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF TMPRSS6 GENE | |
| EP2684167A4 (en) | COMPOSITIONS AND METHODS USEFUL IN THE TREATMENT OF DISEASES | |
| HK1198157A1 (en) | Urease inhibitor formulations | |
| EP2705107A4 (en) | METHODS AND COMPOSITIONS FOR HEAT TRANSFER | |
| HK1199252A1 (en) | Inhibitors of nedd8-activating enzyme nedd8- | |
| EP2741823A4 (en) | METHOD AND COMPOSITIONS FOR IMPROVING SEED FUNCTIONALITY | |
| ZA201207226B (en) | Compositions and methods for treating viral diseases | |
| SG11201402899TA (en) | Methods and compositions for treating viral diseases | |
| GB201114017D0 (en) | Inhibitors against endosomal/ysosomal enzymes | |
| HK1199617A1 (en) | Compositions and methods for treating viral diseases | |
| GB201110658D0 (en) | Improved process and compositions |